Registry of patients treated for blood clots
Official title: Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered
Run by Mayo Clinic · NCT03504007 · Data updated 2026-11-12
This study collects information from patients with blood clots to see how well they respond to treatment and to ensure they get the right care quickly.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | March 1, 2013 |
| Main results expected | March 2033 |
| Study ends | March 2033 |
| Registry record updated | April 27, 2026 |
| Trial ID | NCT03504007 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with acute VTE who begin anticoagulation treatment within 14 days of diagnosis.
✕Probably not a fit
Patients already on anticoagulation for other reasons or those enrolled in other anticoagulation trials may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry collects data on patients diagnosed with venous thromboembolism (VTE) at the Mayo Clinic's Thrombophilia Clinic. It employs a standardized approach to assess and treat patients with acute deep vein thrombosis and pulmonary embolism, ensuring timely anticoagulation therapy. The study monitors outcomes such as recurrence rates, bleeding events, and survival during the treatment period. Patients receive personalized care based on guidelines, with immediate access to necessary medications.
Why it matters
Potential benefit: If successful, this registry could improve treatment protocols and patient outcomes for those suffering from VTE.
How similar studies have gone: Other registries focusing on anticoagulation therapy for VTE have shown success in improving patient outcomes and treatment adherence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • VTE seen at Thrombophilia Clinic and treatment with anti-coagulant is started within 14 days of VTE diagnosis date. Exclusion Criteria: * Patients already on anticoagulation for other reasons or enrolled into anticoagulation clinical trials.
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Damon Houghton, MD, MS — Mayo Clinic
- Study coordinator: Damon Houghton, MD, MS
- Email: vteregistry@mayo.edu
- Phone: 507-266-6717
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE
This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.
-
Bedside saline-contrast electrical impedance tomography for diagnosing acute pulmonary embolism
This study will test whether a bedside saline-contrast electrical impedance tomography (EIT) scan can diagnose acute pulmonary embolism in adults with suspected PE and respiratory failure.
-
Real-world use of the EkoSonic Endovascular System for acute pulmonary embolism in Chinese patients
This study tests whether the EkoSonic Endovascular System is safe and effective for Chinese patients with acute pulmonary embolism in routine clinical care.
-
Healthy living strategies to help recover from pulmonary embolism
This study tests if two healthy living strategies can help people recover better after being hospitalized for a pulmonary embolism.
-
Registry of patients with acute cardiovascular disease in a cardiac intensive care unit
This study is looking at patients with serious heart conditions in the Cardiac Intensive Care Unit to see how they do during and after their hospital stay.
-
Using 129Xe MRI to study lung and blood conditions
This study is testing how a special MRI using 129Xe gas can help us understand lung and blood conditions better by looking at healthy people and those with specific lung diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.